Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma

Summary

This is a single-center, open-label study conducted in subjects with relapsed or refractory CD30-positive lymphoma, with priority given to Hodgkin lymphoma and anaplastic large cell lymphoma.

Timeline

Start

2025-03-04

Primary completion

2027-03-31

Completion

2029-03-31

Outcome

Outcome not reported

Stopped: “The main consideration is the allocation of company resources, We can only terminate this research.”

Drugs

Indications